Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales
The European Journal of Health Economics, 05/17/2012
Brown RE et al. – Lenalidomide plus dexamethasone (LEN/DEX) is a cost effective oncology therapy from the perspective of the NHS for MM patients with one prior treatment.



